This essay summarizes a lecture presented on October 19th, 2017, during the 58th Annual Meeting of the Japanese College of Angiology in Nagoya, Japan. The lecture summarizes several instances where the absence of relaxations of isolated blood vessels in response to endothelium-dependent vasodilator agonists, which cause activation of endothelial nitric oxide synthase (eNOS) and consequent production of endothelium-derived nitric oxide (NO) and stimulation of soluble guanylyl cyclase (sGC) in underlying vascular smooth muscle, or hypoxia are curtailed or reversed to endothelium-dependent contractions. Chosen examples include selective dysfunction of eNOS activation in regenerated endothelial cells, unresponsiveness of vascular smooth muscle cells to NO during subarachnoid hemorrhage, and biased activation of sGC in vascular smooth muscle cells during acute exposure to hypoxia. The main message of this essay is that absence, blunting, or reversal of endotheliumdependent relaxations in response to vasodilator agonists cannot necessarily be interpreted as a sign of endothelial dysfunction. (This is a review article based on the invited lecture of the 58th Annual Meeting of Japanese College of Angiology.)
Introduction
When Professor Kimihiro Komori, the organizer of the 58th Annual Meeting of the Japanese College of Angiology, invited me to deliver a lecture and write this essay, obviously, I was flattered and accepted with pleasure, as he has been an important collaborator during my years at the Mayo Clinic in Rochester (MN, USA) and afterwards became a long-time friend. I intuitively knew that I would be expected to summarize the important protective role of endothelial cells in controlling local vasomotor control in health and vascular disease, since this has been the major interest of my group(s) during the last four decades. Central to this protective role of endothelial cells is endothelial nitric oxide synthase (eNOS; Fig. 1 ), when activated, generates nitric oxide (NO) besides other endotheliumderived relaxing factors (EDRFs; e.g., prostacyclin, hydrogen peroxide) and signals (e.g., ionic changes that evoke endothelium-dependent hyperpolarization [EDH] ) that modulate responsiveness of the underlying vascular smooth muscle cells. When endothelial cells become dysfunctional with aging, obesity, and/or disease (e.g., diabetes and hypertension), the protective effect of NO is attenuated, which sets the stage for initiation of vasospasm and emergence of atherosclerosis. [1] [2] [3] [4] [5] [6] When preparing my lecture, and thus this essay, I selected to address a misinterpretation often made from in vivo observations of endothelial function and dysfunction, particularly in humans where proper analysis is difficult. Indeed, too frequently, abnormal responses to endothelium-dependent vasodilators, in particular those to the gold-standard acetylcholine, 7) are viewed as an indicator solely of dysfunctional NO release. Although this clearly can be the case, abnormal responses to endothelium-dependent vasodilators can also be due to either unresponsiveness of the vascular smooth muscle to the relaxing effect of NO or to the paradoxical contractions initiated by the endothelial mediator. Examples, based on own experience, of those three possible reasons for apparent endothelial dysfunction are presented below.
Insufficient NO
The essential role of eNOS as a source of NO and its regulation ( Fig. 1) as well as the impact of the endothe-lial mediator on its main target, soluble guanylyl cyclase (sGC) in underlying vascular smooth muscle cells (Fig. 2) have been reviewed extensively elsewhere. 5, 6) Blood flowing through arteries and veins is an obvious source of signals that affect the endothelial cells, due not only to the shear stress that blood flow exerts but also the vasoactive substances such as catecholamines, vasopressin, insulin, and adiponectin that are contained within blood (Fig. 2) . (C) When sufficient L-Arg and BH 4 bind to coupled NOS, the electron (e − ) flux provided by nicotinamide adenine dinucleotide phosphate (NADPH) passes through FAD, FMN, CaM, and Heme Fe and is eventually used in NO production. BH 4 is essential for eNOS coupling. Activity of the enzyme is increased when calcium ions (Ca 2+ ) bind to calmodulin. Lower: Principal post-translational modifications that enhance or reduce enzymatic activity and thus favor or reduce endothelium-dependent relaxations, respectively, are indicated in green and red, respectively. Cyst: cysteine; My: N-myristoylation (at glycine 2); NAG: N-acetyl glucosamine; P: phosphorylation; Pa: thiopalmitoylation (at cysteines 15 and 26); Thr: threonine; Tyr: tyrosine; Ser: serine; SNO: S-nitrosylation; SSG: S-glutathionylation (Reproduced from Reference 5 by permission of the American Heart Association.)
NO from Good to Bad ). Phosphorylation events that enhance or reduce enzymatic activity and thus favor or reduce endothelium-dependent relaxations, respectively, are indicated in green and red, respectively. Endothelial cell membrane receptors are coupled to the activation of eNOS through different G proteins (Gi and Gq, inhibited or not, respectively, by pertussis toxin). In addition to eNOS, NO can be produced from nitrate by cytochrome P450 reductase (CPR). Once released, NO exerts a protective effect beyond its direct control of vascular tone by inhibiting (downward arrows) a number of processes favoring vasospasm and initiation of atherosclerosis. Right: Dysfunctional endothelial cells. In regenerated endothelial cells, the overexpression of fatty acid-binding protein A (A-FABP) leads to increased production of reactive oxygen species (ROS), favoring the formation of oxidized low-density lipoproteins (oxLDL), which interrupts (−) the Gi-mediated activation of eNOS. In addition, if Rho-kinase and protein kinase C (PKC) are activated, the ensuing phosphorylation events reduce eNOS activity. As a consequence, a number of processes are disinhibited (upward arrows), which favor the initiation of vasospasm and atherosclerosis. α: alpha adrenergic receptor; ADP: adenosine diphosphate; AT II: angiotensin II; B: bradykinin receptor; DAG: diacylglycerol; E: epinephrine (adrenaline); ET-1: endothelin-1; EDCFs: endothelium-derived vasoconstrictor prostanoids; 5HT: serotonin (5-hydroxytryptamine); G: coupling proteins; LDL: low-density lipoprotein; NE: norepinephrine (noradrenaline); P: purinoceptor; PAR: protease-activated receptor; R: receptor; TRP: transient potential receptor; TX: thromboxane; S100A1: protein S100A1; STIM 1 : SR-transmembrane protein stromal interaction molecule 1; VEGF: vascular endothelial growth factor (Reproduced from Reference 5 by permission of the American Heart Association.)
NO from Good to Bad
Among the latter, products released by aggregating platelets (serotonin [5-hydroxytryptamine, 5-HT], adenosine triphosphate [ATP], and adenosine diphosphate [ADP]) or formed during blood coagulation (thrombin) evoke endothelium-dependent relaxations. 5, 6) Thus, when platelets aggregate in vitro in the vicinity of endothelial cells, they evoke such relaxations of isolated animal and human arteries and veins, by virtue of their ability to release serotonin and ADP in amounts that are sufficient to activate eNOS [8] [9] [10] [11] [12] [13] [14] (Fig. 3) . The endothelial cell membrane 5-HT 1D responding to serotonin released by aggregating platelets are coupled to eNOS by G i proteins, whereas the P 2y purinoceptors activated by ADP as well as ATP are linked to the enzyme by G q proteins 12, 13, 15) (Fig. 3, Left) . When the endothelial lining is absent, such as that occurs following injury, the vasoconstrictors serotonin and thromboxane A 2 released by the aggregating platelets reach vascular smooth muscle cells and lead to their contraction, initiating the vascular phase of hemostasis. NO-mediated responses to aggregating platelets are facilitated by chronic intake of ω-3 polyunsaturated fatty acids but are reduced with high-fat/high-cholesterol diets. [16] [17] [18] [19] In mature arteries and veins, endothelial cells form a tight monolayer and remain quiescent for years. I remem- ber reading a report of autopsies on young healthy adults, all victims of road accidents, stressing the point that signs of endothelial cell turnover were observed only in people older than thirty years of age; unfortunately, I lost track of this reference and thus cannot share it with the readers. However, sooner or later, apoptotic programming initiates detachments of endothelial cells, which are removed by blood flow. This turnover is most prominent in areas of the vascular tree exposed to higher shear stress and is accelerated by aging, exposure to chronic increases in arterial pressure (i.e., hypertension), and prolonged oxidative stress such as that occurs in diabetes. Disruption of the endothelial lining is also unavoidable during acute cardiological procedures, angioplasty in particular, 12, 13) heart transplantation, 20, 21) and venous grafting. 22, 23) Denuded/injured parts of the intima are rapidly covered by regenerated endothelial cells that originate from cells at the rims of injury or are derived from circulating endothelial progenitor cells. [4] [5] [6] However, these regenerated endothelial cells are a prototypical example of selective endothelial dysfunction due to decreased production of NO in response to aggregating platelets. This conclusion is based on repeated observations in porcine coronary circulation. When relining of the endothelial surface was complete four weeks after in vivo angioplasty, preparations covered with regenerated endothelium were characterized by a reduction in relaxation in response to aggregating platelets, serotonin, α 2 -adrenergic agonists, and thrombin, whereas their response to ADP or bradykinin remained unchanged [4] [5] [6] [12] [13] [14] (Fig. 4) . These findings prompted the concept that selective dysfunction of G i -related, endothelium-dependent relaxations are an unavoidable consequence of the regenerative process (Fig. 3 , Right) [4] [5] [6] and a characteristic of regenerated endothelial cells. In vitro, this selective endothelial dysfunction results in exaggerated vasoconstrictor responses to serotonergic activation by aggregating platelets (Fig. 4A) and serotonin. In vivo, this long-lasting dysfunction favors hyperconstriction, i.e., vasospasm, in response to aggregating platelets or exogenous serotoninergic agonists and favors the formation of atherosclerotic lesions [4] [5] [6] 24) (Fig. 4D) . The molecular mechanisms underlying the selective loss of G i -dependent responses (Figs. 4B and 4C ) have been summarized in detail elsewhere. [4] [5] [6] 24) Nonetheless, these earlier experiments caution against categorizing relaxations/dilatations in response to a single endothelium-dependent agonist as endothelial dysfunction. This is in particular important in the case of acetylcholine which, in many blood vessels, is a full, powerful stimulator of eNOS and thus less likely to be modulated, whereas it simply does not evoke endothelium-dependent, NO-mediated relaxations in other vessels such as porcine and human coronary arteries, and canine basilar arteries. 3)
Insensitivity of Vascular Smooth Muscle despite Sufficient NO Release
Under a number of conditions such as aging, diabetes, hypertension, or prolonged exposure to exogenous NO donors or angiotensin II (Fig. 5, Lower right) , endothelial cells do indeed release NO upon exposure to endotheliumdependent relaxing agents; however, the underlying vascular smooth muscle has become partially or completely insensitive to the vasodilator effect of the mediator. 5) The most convincing example of this situation comes from our group when, many years ago, we investigated the impact of subarachnoid hemorrhage on endothelium-dependent relaxations in the canine basilar artery. [25] [26] [27] In those studies, angiographically confirmed vasospasm of the basilar artery was present seven days after the injection of autologous blood in cisterna magna. Isolated rings of the vasospastic basilar arteries did not relax when exposed to increasing concentrations of vasopressin, unlike the powerful endothelium-dependent vasodilator acetylcholine, or ADP (Fig. 6A) . When we perfused preparations to bioassay NO release, we were quite surprised to observe that the release of endothelium-derived relaxing factors by the vasospastic arteries was comparable to that of healthy controls (Fig. 6B) . Next, we demonstrated that the vascular smooth muscle cells of the vasospastic arteries were indeed significantly less sensitive to authentic NO than control preparations (Fig. 6C) . Finally, we explained this insensitivity by a reduction in the production of 3′,5′-cyclic guanosine monophosphate (cGMP), the second messenger formed by the enzyme sGC, which, as noted earlier, is the main target for NO in vascular smooth muscle cells (Fig. 6D) . Thus, the unavoidable conclusion was that subarachnoid hemorrhage did not cause endothelial dysfunction, since the endothelial cells fulfill their function quite well to release sufficient NO; rather, it prevented the endothelium-derived mediator from inducing the relaxation of the underlying vascular smooth muscle cells. In hindsight, this conclusion is not too surprising since, with the formation of the autologous blood clot at the outside of the basilar artery, hemoglobin released by lysed erythrocytes can diffuse to the vascular smooth Experiments under bioassay conditions. If a layered (i.e., sandwich [7] ) preparation contains no endothelium (upper), acetylcholine (ACh) evokes no response during a contraction by prostaglandin F 2α (PGF 2α ), while acute hypoxia causes relaxation. However, if the layered preparation contains endothelial cells (lower), ACh causes a concentration-dependent relaxation while acute hypoxia evokes an increase in tension (Data from Reference 34). These experiments demonstrate that the signal leading to hypoxic augmentation originates in endothelial cells. Lower (C) Hypoxic augmentation in rings of porcine coronary arteries. The augmentation observed in rings with endothelium under control conditions (Control) is reduced/abolished by endothelium-removal (−EC), by an eNOS-inhibitor (L-NAME) or by an sGC-inhibitor (ODQ). In the presence of L-NAME, the exogenous NO donor detaNONOate reinstalls hypoxic augmentation, an effect which is abrogated by ODQ. In contrast, in the presence of the eNOS-inhibitor, the cell permeable 3′,5′-cyclic guanosine monophosphate (cGMP) analog 8-Br-cGMP does not restore the hypoxic augmentation (Data from Reference 40) . These experiments demonstrate that the release of NO and the activation of sGC, but not the production of cGMP, underlie endothelium-dependent contractions in response to acute hypoxia. Lower (D) Production of 3′,5′-cyclic inosine monophosphate (cIMP, upper) and cGMP (lower) by porcine coronary arteries under normoxic (left) and hypoxic (right) conditions (Data from Reference 42) . These experiments demonstrate that hypoxia augments the release of the non-canonical sGC-product cIMP, while, if anything, decreasing that of cGMP.
muscle cells and interfere with the enzymatic activity of sGC in these cells. In addition, caution is warranted in analysis of the impact of adventitial events on endothelial function per se. For example, it is not always easy to demonstrate that inflammatory responses in periadventitial adipose tissue (PVAT) and the release of adipokines from that site 28, 29) truly affect the release of NO by endothelial cells. In particular, in larger arteries with a thick media, these adipokines have a long way to go before they can reach the endothelium and alter the responsiveness of vascular smooth muscle cells that they encounter first. In any case, I never accept conclusions concerning endothelial dysfunction if reduced relaxations (in vitro) or dilatations (in vivo) to endothelium-dependent vasodilators are not paralleled by data demonstrating unchanged responses to exogenous NO donors.
Altered Responsiveness of Vascular Smooth Muscle despite Sufficient NO Release
The prototypical example of a situation where NO released by endothelial cells results in vasoconstriction due to altered responsiveness of the underlying vascular smooth muscle is endothelium-dependent contractions in response to hypoxia. For almost half a century, I have been puzzled by the observation that acute hypoxia, which I considered to be the ultimate vasodilator signal as a physiologist, in fact can cause temporary contractions of certain isolated blood vessels 30, 31) (Fig. 7A) . A breakthrough came when we discovered that such responses required the presence of endothelial cells in the isolated preparations studied. 32, 33) The next step was the demonstration that the release of an endothelium-derived factor was indeed pivotal for evoking hypoxic augmentation of vasoconstrictor responses under bioassay conditions 34) (Fig. 7B) . Contractions of isolated blood vessels in response to the release of endothelium-derived contracting factors (EDCFs; mainly vasoconstrictor prostanoids and possibly endothelin-1) is well established, but such responses are exacerbated in the absence of NO. 2, [35] [36] [37] In contrast, a series of pharmacological experiments using inhibitors of both eNOS and sGC demonstrated the requirement of endothelium-derived NO and subsequent activation of sGC as prerequisites for hypoxic augmentation [38] [39] [40] (Fig. 7C) . However, the hypoxic augmentation could not possibly be attributed to increased production of cGMP, the canonical product of sGC. 40) Revelation came when we found that sGC could switch from guanosine as a substrate (to produce cGMP) to inosine (to produce 3′,5′-cyclic inosine monophosphate [cIMP]) under certain circumstances. 41) Sure enough, when measuring the production of both cGMP and cIMP during hypoxic augmentations, it became apparent that the levels of the former, if anything, were reduced, whereas those of the latter were increased significantly (Fig. 7D) 42) ; the obvious counterintuitive conclusion of these experiments was that the non-canonical sGC-product cIMP was responsible for the endothelium-dependent augmentations caused by acute exposure to hypoxia. An identical interpretation was reached when analyzing the endothelium-dependent augmentations observed with the natural product thymoquinone. 43) These experiments lead to the conclusion that hypoxia and certain quinones biased the activity of sGC in vascular smooth muscle cells (Fig. 5 , Lower left), although it was not easy for our interpretation to bypass the criticism of reviewers. 5, [44] [45] [46] We are currently investigating intracellular target(s) of hypoxia and quinones that cause the biased activity of sGC, with a particular interest in the possible role of the enzyme NAD(P) H: quinone acceptor oxidoreductase-1 (NQO-1). Nonetheless, the epic mission to uncover the mechanism underlying endothelium-dependent contractions to acute hypoxia is probably the best example in a long career that one should never forget the odd, unexplainable behavior of an isolated blood vessel 30) but should revisit over the years as a satisfactory explanation becomes available with the progression of knowledge and technology. In the case of hypoxic augmentations, this is not only a matter of science for the sake of science as we were able to demonstrate earlier that in coronary circulation previous ischemia/reperfusion markedly exaggerates the development of hypoxic augmentations and thus facilitates hypoxic vasospasm, 39) an exaggeration which helps, at least us, to better understand why patients with sleep apnea exhibit a greater propensity for acute coronary syndrome.
Conclusion
The three examples summarized above yield the following lessons on possible alterations in the eNOS-NO-sGC pathway while being challenged with abnormal responses, i.e., relaxations (in vitro) or dilatations (in vivo), to accepted endothelium-dependent vasodilators: a) never trust the absence of differences if only one agonist is used, especially acetylcholine; b) always ensure that the responsiveness of the underlying vascular smooth muscle cells to NO is unchanged; and c) also consider that the unexpected responses, in particular endothelium-dependent contractions, can be due to biased responses of target(s) for NO in vascular smooth muscle cells.
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